For years, Palantir Technologies (NASDAQ: PLTR) was the AI stock investors had to explain away. Its founders held outsized voting control. Its CEO sounded more like a philosopher than a salesman. And it refused to build its own frontier model. The market treated these as quirks
Analysts See Double-Digit Upside for These 3 StocksNasdaq (NASDAQ:NDAQ) CFO Sarah Youngwood said the company sees a constructive macroeconomic backdrop, citing investment in artificial intelligence and digital technologies, resilient consumers and corporate earnings that she said
AI Data Centers Are Splitting Winners From Pretenders in Infrastructure StocksBlackstone (NYSE:BX) CFO Michael Chae said the firm sees a constructive backdrop for corporate profits, investment deployment and fundraising, citing accelerating earnings growth, expanding margins and
3 Stocks to Buy and Hold for Higher Interest RatesDoug Petno, co-president and CEO of the Commercial and Investment Bank at JPMorgan Chase & Co. (NYSE:JPM), said the bank expects broad-based strength in investment banking and markets during the third quarter, while emphasizing th
Blueprint for a Boom: SEC Clears the Crypto RunwayRobinhood Markets (NASDAQ:HOOD) is pursuing a strategy centered on expanding access to financial asset ownership, with priorities spanning active trading, broader consumer financial services and international infrastructure, Chief
Why AppLovin’s CEO Is Selling While Quantum Insiders Are BuyingServiceTitan (NASDAQ:TTAN) reported fiscal second-quarter 2027 revenue growth of 21% and record free cash flow, while outlining a broader investment push behind its AI-driven Max platform and internal “Software Factor
Insider purchases are one of many signals that investors can use to gauge the outlook of a stock. While insider buys are just one piece of a larger picture, they can be particularly notable when made by a company’s top executive: the CEO.
Amid a run of poor performance in 2026,
Bausch Health: A Buyout Bid Could Be the Ticket to Unlock ValueBausch + Lomb (NYSE:BLCO) said it plans to advance a dual-action dry eye treatment into Phase III development after a Phase II study showed statistically significant improvement in corneal staining at day 15, although
With companies staying private longer, meaning most are going public as bigger, more mature, companies. The data backs this up. Although, the “why” is still being argued over.
MarketBeat Week in Review – 02/23 - 02/27Hinge Health (NYSE:HNGE) reported second-quarter 2026 revenue of $213 million, up 53% from a year earlier and above the company’s prior guidance range of $200 million to $202 million. The digital healthcare company also raised its full-yea
While fear and panic have gripped the AI trade and broader technology sector, one corner of the market has recently made new 52-week highs. The Financial Select Sector SPDR Fund (NYSEARCA: XLF) recently touched a fresh all-time high of $57.60 before easing back into the mid-$50s
3 2021 IPOs Likely To Notch Further Big Price Gains Ryan Specialty (NYSE:RYAN) reported second-quarter revenue growth of 7.2% to $917 million, supported by 6.7% organic growth and modest contributions from acquisitions, as the specialty insurance services company navigated pricin
3 of the Most Highly Anticipated IPOs of 2026Franklin Resources (NYSE:BEN) reported positive long-term net inflows across every asset class and geography during its fiscal third quarter ended June 30, 2026, as the asset manager cited broad demand for public markets, private marke
Donnelley Financial Solutions (NYSE:DFIN) reported second-quarter 2026 net sales of $224.2 million, up 2.8% from a year earlier, as growth in software solutions and capital-markets transaction activity more than offset continued declines in print and distribution revenue. The com
AI Is Selling Off, But These 5 Stocks Could Benefit NextRobinhood Markets (NASDAQ:HOOD) reported record second-quarter revenue, net deposits and platform engagement, while outlining continued investments in trading products, banking, international expansion and blockchain-based f
Bausch Health: A Buyout Bid Could Be the Ticket to Unlock ValueBausch + Lomb (NYSE:BLCO) reported second-quarter 2026 revenue growth across its vision care, surgical and pharmaceutical businesses, while raising its full-year revenue and adjusted EBITDA outlook. The company said i
Preparing for an Initial Public Offering (IPO) is arguably the most significant undertaking in a company’s journey. At the core of this monumental task lies the financial health of the company, and steering this ship through uncharted waters are the accountants.
Lineage, the world’s largest real estate investment trust for temperature-controlled warehouses, celebrated its initial public offering on Thursday, July 25 – marking the largest IPO of the year so far.